Potent P2Y12 inhibitors versus clopidogrel to predict adherence to antiplatelet therapy after an acute coronary syndrome: insights from IDEAL-LDL.
Sign Up to like & getrecommendations! Published in 2022 at "Reviews in cardiovascular medicine"
DOI: 10.31083/j.rcm2303081
Abstract: BACKGROUND Superiority of potent P2Y12 inhibitors over clopidogrel after an acute coronary syndrome (ACS) has been well established, however potent P2Y12 inhibition is responsible for more adverse events, which may influence patient adherence to treatment.… read more here.
Keywords: adherence; potent p2y12; potent; therapy ... See more keywords